Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis

• Главные авторы: Ju Li (Автор), Zhongyuan Zhang (Автор), Xinhua Wu (Автор), Jie Zhou (Автор), Deqian Meng (Автор), Ping Zhu (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-11-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background: Adalimumab, golimumab, infliximab, certolizumab, and etanercept are five anti-tumor necrosis factor (anti-TNF) medicines that have been approved for use in rheumatology. Apart from their well-established therapeutic usefulness, -it is unclear to what extent -they are linked to an increas...